-
VERV Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Verve Therapeutics (VERV)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 177.33 mm | 177.33 mm | 177.33 mm | 177.33 mm | 177.33 mm | 177.33 mm |
Cash burn (monthly) | (no burn) | 2.80 mm | 18.69 mm | 19.06 mm | 13.62 mm | 13.14 mm |
Cash used (since last report) | n/a | 7.97 mm | 53.20 mm | 54.24 mm | 38.75 mm | 37.41 mm |
Cash remaining | n/a | 169.36 mm | 124.14 mm | 123.09 mm | 138.58 mm | 139.93 mm |
Runway (months of cash) | n/a | 60.4 | 6.6 | 6.5 | 10.2 | 10.6 |
13F holders | Current |
---|---|
Total holders | 171 |
Opened positions | 23 |
Closed positions | 29 |
Increased positions | 63 |
Reduced positions | 54 |
13F shares | Current |
---|---|
Total value | 426.25 bn |
Total shares | 102.30 mm |
Total puts | 157.30 k |
Total calls | 67.37 k |
Total put/call ratio | 2.3 |
Largest owners | Shares | Value |
---|---|---|
GOOG Alphabet | 12.35 mm | $69.65 bn |
GV 2017 | 12.35 mm | $145.60 mm |
BlackRock | 7.53 mm | $42.44 bn |
Biotechnology Value Fund L P | 6.90 mm | $31.07 mm |
BVF | 6.90 mm | $38.94 bn |
Vanguard | 4.01 mm | $22.60 bn |
Casdin Capital | 4.00 mm | $22.54 bn |
Millennium Management | 3.92 mm | $22.10 bn |
Schonfeld Strategic Advisors | 3.79 mm | $21.37 bn |
STT State Street | 3.24 mm | $18.25 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Jan 25 | Jason Politi | RSU Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 40,000 |
8 Jan 25 | Jason Politi | Stock Option Common Stock | Grant | Acquire A | No | No | 6.01 | 225,000 | 1.35 mm | 225,000 |
8 Jan 25 | Joan Nickerson | RSU Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 40,000 |
8 Jan 25 | Joan Nickerson | Stock Option Common Stock | Grant | Acquire A | No | No | 6.01 | 225,000 | 1.35 mm | 225,000 |
8 Jan 25 | Andrew D. Ashe | RSU Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 40,000 |
8 Jan 25 | Andrew D. Ashe | Stock Option Common Stock | Grant | Acquire A | No | No | 6.01 | 225,000 | 1.35 mm | 225,000 |
8 Jan 25 | Sekar Kathiresan | Stock Option Common Stock | Grant | Acquire A | No | No | 6.01 | 150,000 | 901.50 k | 150,000 |
8 Jan 25 | Sekar Kathiresan | RSU Common Stock | Grant | Acquire A | No | No | 0 | 120,000 | 0.00 | 120,000 |
8 Jan 25 | Sekar Kathiresan | Stock Option Common Stock | Grant | Acquire A | No | No | 6.01 | 488,000 | 2.93 mm | 488,000 |
8 Jan 25 | Allison Dorval | Stock Option Common Stock | Grant | Acquire A | No | No | 6.01 | 75,000 | 450.75 k | 75,000 |